Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Health technology symbols : PFE save search
European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 0.0%
H: 1.92%
C: 1.0%
emblaveo treatment for infections
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 0.11%
H: 0.38%
C: -0.04%
meeting
NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects
Published: 2024-04-09 (Crawled : 18:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.97%
H: 0.26%
C: -0.75%
for
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager
Published: 2024-04-08 (Crawled : 17:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
DOW | $56.74 -0.44% 0.34% 2.4M
|
Process Industries
|
| O: 0.44%
H: 0.4%
C: -0.72%
dean
ViiV Healthcare announces U.S. FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
fda approval for hiv living
Bluerock Value Exchange Fully Subscribes $46.5 Million Diversified Industrial Portfolio I DST
Published: 2024-03-27 (Crawled : 13:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 0.43%
H: 0.81%
C: 0.25%
million
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
Published: 2024-03-26 (Crawled : 21:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 0.43%
H: 0.81%
C: 0.25%
therapeutics
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.18%
H: 0.4%
C: -0.14%
pharmaceuticals
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Published: 2024-03-18 (Crawled : 21:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.18%
H: 0.4%
C: -0.14%
ARVN | $34.0 -2.58% -2.77% 630K
|
Health Technology
|
| O: -3.22%
H: 4.58%
C: 3.23%
medical
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 1.0%
H: 1.41%
C: -0.25%
disease pneumococcal children
Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
adcetris positive trial
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.21%
H: 0.11%
C: -1.06%
LLY | News | $745.69 1.96% 0.04% 1.4M
|
Health Technology
|
| O: 0.9%
H: 2.03%
C: 1.89%
VERU | $1.275 0.39% 0.0% 2.6M
|
Health Technology
|
| O: -0.53%
H: 2.22%
C: -3.59%
ALT | $7.57 1.34% 1.19% 2.8M
|
Commercial Services
|
| O: 0.3%
H: 11.41%
C: 9.8%
medical program
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Published: 2024-03-07 (Crawled : 12:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 0.04%
H: 0.44%
C: -1.51%
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: -2.08%
H: 0.13%
C: -0.57%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.36%
H: 0.34%
C: -0.54%
XFOR | $1.23 -9.56% -11.02% 3.3M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -4.98%
EYPT | News | $17.57 3.66% 3.5% 860K
|
Health Technology
|
| O: 2.56%
H: 1.37%
C: -4.13%
AQST | $4.28 -2.28% -2.7% 1.6M
|
Health Technology
|
| O: 1.79%
H: 12.3%
C: 10.94%
ALKS | $24.26 0.79% 0.78% 1.2M
|
Health Technology
|
| O: 1.11%
H: 0.96%
C: 0.65%
Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024
Published: 2024-03-06 (Crawled : 01:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 3.14%
H: 1.49%
C: 1.08%
KZR | $0.826 0.49% 0.15% 520K
|
Health Technology
|
| O: 1.94%
H: 0.0%
C: -1.9%
financial results
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference - March 5, 2024
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.08%
H: 2.13%
C: 0.81%
conference
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses
Published: 2024-03-04 (Crawled : 21:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -1.09%
H: 0.61%
C: -1.56%
trial
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: 0.11%
H: 0.44%
C: -1.88%
abrysvo positive rsv
Kalderos Attracts Two Recognized Industry Leaders to Board of Directors
Published: 2024-02-27 (Crawled : 14:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.22%
H: 0.29%
C: -0.85%
leaders
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
PFE | News 4 | $26.32 0.23% 0.15% 20M
|
Health Technology
|
| O: -0.22%
H: 0.29%
C: -0.85%
ARVN | $34.0 -2.58% -2.77% 630K
|
Health Technology
|
| O: 0.0%
H: 1.25%
C: -1.6%
year update financial results
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.